Suppr超能文献

早期膈下霍奇金淋巴瘤的放射治疗:澳大利亚和新西兰的经验

Radiotherapy for early infradiaphragmatic Hodgkin's disease: the Australasian experience.

作者信息

Barton M, Boyages J, Crennan E, Davis S, Fisher R J, Hook C, Johnson N, Joseph D, Khoo V, Liew K H, Morgan G, O'Brien P, Pendlebury S, Pratt G, Quong G, Roos D E, Thornton D, Trotter G, Walker Q, Wallington M

机构信息

Division of Radiation Oncology, Westmead Hospital, NSW, Australia.

出版信息

Radiother Oncol. 1996 Apr;39(1):1-7. doi: 10.1016/0167-8140(96)01715-x.

Abstract

PURPOSE

To review the Australasian results of Stage I and IIA Infradiaphragmatic Hodgkin's Disease (IHD) treated solely by irradiation.

METHODS AND MATERIALS

Eligible patients had IHD only and were treated by irradiation with curative intent over the period of 1969 to 1988. Ten radiation oncology centres from within Australia and New Zealand were surveyed for patient, tumour and treatment variables. Disease free rates, survival and complications were analysed.

RESULTS

106 patients with IHD were studied. The average potential follow up was 9.4 years. The male to female ratio was 3.3:1. The median age was 37.5 years. Histological subgroups were as follows; lymphocyte predominant 43%, mixed cellularity 21%, lymphocyte depleted 5%, nodular sclerosing 27% and unclassifiable 4%. Fifty nine patients had laparotomy of which 22 (37%) were positive for tumour. Nine laparotomies were performed for diagnosis and the remainder for staging. One patient was up-staged by laparotomy and three were down-staged. Sixty-eight patients presented with inguinal disease alone, five with abdominal disease alone, 19 with two sites of involvement and 12 with inguinal, pelvic and abdominal disease. In two patients the site was unknown. There was no correlation between site of involvement, age, sex or histological subtype. Forty seven cases were clinically staged (CS) as follows: CS IA-23, CS IIA-24. The other 59 were pathologically staged (PS) as follows: PS IA-37, PS IB-1, PS IIA-21. Treatment consisted of involved field alone (16), inverted Y (68), inverted Y and spleen (13), para-aortic irradiation only (3), or total nodal irradiation (6). Mean dose was 37 Gy. There were 30 recurrences to give an acturial 10-year disease-free rate of 70%. In multivariate analysis lower number of tumour sites, lymphocyte predominant histology and higher dose were all significantly correlated with higher disease free rates. Eight patients died of Hodgkin's disease and 19 of other causes. The 10-year overall survival rate was 71%. Older age and higher number of disease sites were significantly correlated with shorter survival. Fourteen of 30 relapses may have been avoidable by the use of total nodal irradiation. In particular ten of 21 patients with abdominal disease relapsed in nodal sites which would have been covered by total nodal irradiation.

CONCLUSIONS

The rate of control in IHD could perhaps be improved by avoiding involved field irradiation or by aggressive therapy with total nodal irradiation or combined modality chemo-irradiation in Stage II disease. Staging laparotomy does not appear to be indicated.

摘要

目的

回顾仅通过放疗治疗的Ⅰ期和ⅡA期膈下霍奇金病(IHD)在澳大拉西亚地区的治疗结果。

方法和材料

符合条件的患者仅患有IHD,并在1969年至1988年期间接受了根治性放疗。对澳大利亚和新西兰的10个放射肿瘤中心的患者、肿瘤和治疗变量进行了调查。分析了无病生存率、生存率和并发症。

结果

对106例IHD患者进行了研究。平均潜在随访时间为9.4年。男女比例为3.3:1。中位年龄为37.5岁。组织学亚组如下:淋巴细胞为主型43%,混合细胞型21%,淋巴细胞消减型5%,结节硬化型27%,无法分类型4%。59例患者接受了剖腹探查术,其中22例(37%)肿瘤阳性。9例剖腹探查术用于诊断,其余用于分期。1例患者因剖腹探查术而上调分期,3例下调分期。68例患者仅表现为腹股沟病变,5例仅表现为腹部病变,19例有两个部位受累,12例有腹股沟、盆腔和腹部病变。2例患者病变部位不明。受累部位、年龄、性别或组织学亚型之间无相关性。47例患者临床分期(CS)如下:CS IA - 23例,CS IIA - 24例。其他59例患者病理分期(PS)如下:PS IA - 37例,PS IB - 1例,PS IIA - 21例。治疗包括仅累及野放疗(16例)、倒Y野放疗(68例)、倒Y野加脾放疗(13例)、仅主动脉旁放疗(3例)或全淋巴结放疗(6例)。平均剂量为37 Gy。有30例复发,实际10年无病生存率为70%。多因素分析显示,肿瘤部位数量较少、淋巴细胞为主型组织学和较高剂量均与较高的无病生存率显著相关。8例患者死于霍奇金病,19例死于其他原因。10年总生存率为71%。年龄较大和疾病部位数量较多与较短的生存期显著相关。30例复发患者中有14例可能通过全淋巴结放疗避免复发。特别是21例腹部病变患者中有10例在全淋巴结放疗可覆盖的淋巴结部位复发。

结论

对于IHD,通过避免累及野放疗,或在Ⅱ期疾病中采用积极的全淋巴结放疗或综合放化疗,可能会提高控制率。分期剖腹探查术似乎并无必要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验